SALSA MLPA P476 ZNRF3 probemix

Application: Adrenocortical tumours and other solid tumours
Region: ZNRF3, 22q12.1
[Login for My Products]

Item no. Description Price
P476-025R SALSA MLPA P476 ZNRF3 probemix – 25 rxn € 243
P476-050R SALSA MLPA P476 ZNRF3 probemix – 50 rxn € 486
P476-100R SALSA MLPA P476 ZNRF3 probemix – 100 rxn € 972
EK1-FAM SALSA MLPA EK1 reagent kit – 100 rxn - FAM € 300
EK1-Cy5 SALSA MLPA EK1 reagent kit – 100 rxn - Cy5 € 300
EK5-FAM SALSA MLPA EK5 reagent kit – 500 rxn - FAM € 1380
EK5-Cy5 SALSA MLPA EK5 reagent kit – 500 rxn - Cy5 € 1380
To perform MLPA, both a probemix and reagent kit are needed.

Description
General information: The SALSA MLPA Probemix P476 ZNRF3 is a research use only (RUO) assay for the detection of deletions and duplications in the ZNRF3 gene.

ZNRF3 is an E3 ubiquitin-protein ligase that acts as a negative feedback regulator of Wnt signalling (Hao et al. 2012). Three independent studies show homozygous deletions of the ZNRF3 gene in 10 to 16% of adrenocortical carcinoma cases (Assié et al. 2014; Juhlin et al. 2015; Zheng et al. 2016). Moreover, in 51% of microsatellite stable colorectal cancers deletion events at the ZNRF3 locus are detected (Bond et al. 2016). Deletions of the ZNRF3 gene are also found in osteoblastoma and prostate cancer (Nord et al. 2013; Robinson et al. 2015).

Probemix content: The SALSA MLPA Probemix P476-A1 ZNRF3 contains 42 MLPA probes with amplification products between 130 and 433 nucleotides (nt). This includes 15 probes for the ZNRF3 gene, plus four flanking probes for upstream genes and five flanking probes for downstream genes. In addition, 18 reference probes are included and target relatively copy number stable regions in various cancer types including adrenocortical carcinoma, colorectal cancer and prostate adenocarcinoma. Complete probe sequences and the identity of the genes detected by the reference probes is available in Table 2b of the product description and online (www.mlpa.com).

This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity Fragments (Q-fragments), two DNA Denaturation Fragments (D-fragments), one Benchmark fragment, and one chromosome X and one chromosome Y-specific fragment. More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol and online at www.mlpa.com.

Product History
Current version: A1, sold since: 2018-07-02.

Version A1: Changes not specified
New Products
P484-ALPL
Hypophosphatasia (HPP)
Improved Products
P278-PCCA-PCCB
Propionic acidemia
P158-JPS
Juvenile polyposis syndrome (JPS)
P072-MSH6-MUTYH
Lynch syndrome; MUTYH-associated polyposis (MAP)
P225-PTEN
PTEN hamartoma tumor syndrome, Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, PTEN-related proteus syndrome, Proteus-like syndrome; (Tumour analysis for research use only)
P128-CYP450
Cytochrome P450
P021-SMA
Spinal muscular atrophy (SMA)
P409-RASA1-EPHB4
capillary malformations, Parkes Weber syndrome
P419-CDKN2A/2B-CDK4
Familial melanoma
P389-MLL2
Kabuki syndrome
P324-22q11
22q11
P202-IKZF1-ERG
Acute lymphoplastic leukemia (ALL), CVID, CML
Newsletter  |  Home  |  Privacy Policy  |  Terms and Conditions  |  Search  |  Sitemap  |  Copyright © 2019 MRC-Holland